Oritavancin injection is used for treating adults with acute skin infections caused by gram-positive bacteria.
Oritavancin is an antibacterial drug used for the treatment of adults with acute bacterial skin and skin related infections caused or suspected to be caused by susceptible gram-positive bacteria
Oritavancin should not be used in patients:
If there is an allergy to oritavancin
Intravenous heparin injection (unfractionated) should not be taken for 48 hours after oritavancin administration.
Pregnancy and breastfeeding women
Should not be used in patients below 18 years.
Oritavancin is given as 1200 mg single dose intravenous infusion over 3 hours in patients above 18 years to treat acute skin infections caused by gram-positive bacteria.
Oritavancin intravenous infusion should be given by a healthcare professional.
Three 400 mg vials should be reconstituted and diluted to prepare 1200 mg intravenous dose.
Aseptic technique should be followed to reconstitute this solution.
5% dextrose in sterile water(D5W) should be used for dilution.
Normal saline should not be used as it is incompatible with oritavancin.
Foaming should be avoided and ensure that all oritavancin powder is completely reconstituted in solution.
Vial should be clear, colorless to a pale-yellow solution.
Drugs prepared at a basic or neutral pH are found to be incompatible with oritavancin.
Oritavancin should not be administered simultaneously with other intravenous drugs through a common intravenous port.
The diluted solution in an infusion bag should be used within 6 hours when stored at room temperature, or within 12 hours when refrigerated at 2 to 8°C.
The storage time and 3-hour infusion time should not exceed 6 hours at room temperature or 12 hours if refrigerated.
If the same intravenous line is used for sequential infusion of additional drugs, the IV line should be flushed before and after infusion of oritavancin with 5% Dextrose
Oritavancin may prolong the bleeding and clotting time.
Discontinue oritavancin infusion if signs of acute allergy occur.
The rate of infusion should be slowed down if infusion reaction develops.
Patients may develop diarrhea caused by Clostridium difficile.
Alternate antibacterial therapy should be used in patients with confirmed or suspected osteomyelitis.
Gastrointestinal: Diarrhea , nausea, vomiting
Nervous system: Dizziness, headache
Skin: limb and subcutaneous abscess
Others: Injection-related side effects can occur
Lab abnormalities: Blood tests like ApTT, PT, INR and liver enzyme levels should be monitored
Pregnancy -should be used only if benefits are more than risk.
Caution should be exercised when oritavancin is given to a breastfeeding woman.
In case of overdose, supportive measures should be taken. It is unlikely to be removed from the blood by hemodialysis.
Patients should be assured that diarrhea is a common problem caused by antibacterial drugs including oritavancin, which usually resolves when the drug is discontinued. In case of severe watery or bloody diarrhea, patients should contact their healthcare provider.
Concomitant warfarin use: Co-administration of oritavancin with warfarin may result in the increased effect of warfarin, which may increase the risk of bleeding.
Oritavancin vials should be stored at 20ΊC to 25ΊC (68ΊF to 77ΊF).
Subscribe to our Free Newsletters!